Biotech Business - February 9, 2026
Carl Bennet invests SEK 45 million in Medivir
Medivir has completed a directed share issue of SEK 45 million (before issue costs) to Carl Bennet AB, issuing 90 million new shares at SEK 0.50 per share—a 19 percent premium to the closing price on February 5, 2026.
Biotech article - February 5, 2026
Denmark’s regulatory stance seen as an edge for biotechs
Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.
Biotech Business - January 29, 2026
Alvotech reaches settlement agreement with Regeneron and Bayer
Alvotech has reached a licensing and settlement agreement with Regeneron and Bayer, resolving all remaining patent disputes worldwide related to Alvotech’s biosimilar to Eylea 2mg, which is approved for marketing in the European Economic Area, United Kingdom and Japan.
Biotech Business - January 26, 2026
Leqembi Iqlik supplemental BLA granted Priority Review by FDA
BioArctic’s partner Eisai has announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneous autoinjector (SC-AI) as a weekly starting dose has been granted Priority Review by the US Food and Drug Administration (FDA).
Biotech Award - January 23, 2026
Mavatar launches Rare Disease Discovery Award
The aim of the initiative is to strengthen research in rare diseases where access to data and analytical tools remains limited.
Biotech Business - January 20, 2026
Affibody carries out fully guaranteed rights issue
The Board of Directors of the company has resolved to carry out a fully guaranteed rights issue of SEK 307 million.
